Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program

Pediatr Blood Cancer. 2009 Sep;53(3):505-8. doi: 10.1002/pbc.21988.


Vorinostat, a histone deacetylase inhibitor, was evaluated against the in vitro and in vivo childhood solid tumor and leukemia models in the Pediatric Preclinical Testing Program (PPTP). In vitro testing was performed by the DIMSCAN cytotoxicity assay. In vivo, vorinostat was administered intraperitoneally to mice bearing xenografts. Vorinostat demonstrated 2-log cell growth inhibitory activity in vitro, but generally at concentrations not sustainable in the clinic. No objective responses were observed for any of the solid tumor or acute lymphoblastic leukemia xenografts. Preclinical studies with appropriate drug combinations may provide direction for further clinical evaluations of vorinostat against selected pediatric cancers.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology*
  • Cell Line, Tumor
  • Female
  • Humans
  • Hydroxamic Acids / pharmacology*
  • Mice
  • Mice, Inbred BALB C
  • Mice, SCID
  • Vorinostat
  • Xenograft Model Antitumor Assays


  • Antineoplastic Agents
  • Hydroxamic Acids
  • Vorinostat